NCT00530530

ASP8825 - Study in Patients With Restless Legs Syndrome

ASP8825 Phase ⅡStudy-A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP8825 in Patients With Restless Legs Syndrome

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 474 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To demonstrate the superiority of ASP8825 over placebo and the dose response in patients with restless legs syndrome

Detailed description

Three doses of ASP8825 are compared to placebo in efficacy and safety point of view in patients with restless legs syndrome

Conditions

• Restless Legs Syndrome

Interventions

Type	Name	Description
DRUG	ASP8825	oral
DRUG	Placebo	oral

Timeline

• Start date: 2007-09-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2007-09-17
• Last updated: 2014-10-29

Locations

6 sites across 1 country: Japan